{
  "abstract": "Background: Risankizumab is administered via a new modality, so-called on-body injector (OBI). Objectives: To assess the acceptability and the tolerability of OBI-risankizumab therapy, and compare its acceptability with other available modalities in Crohn's disease (CD). Design: Longitudinal multicenter prospective study. Methods: All CD patients from an early access cohort treated with OBI-risankizumab were assessed from the first OBI use (week 0 = W0), W8, W16, and W24. The primary endpoint was acceptability (acceptability numerical scale = ANS). Patients were asked to grade the acceptability of OBI-risankizumab and other modalities of therapeutic maintenance regimen. Results: Among 58 CD patients (79.4% with at least four prior advanced therapies), OBI-risankizumab acceptability was 9.5±1.2 at W0 and remained stable until W24 (p=0.97). OBI-risankizumab acceptability showed a higher acceptability than intravenous infusions (p<0.0001), pen injectors (p<0.001), and syringes (p<0.001), and ranked as the preferred route in 64% of patients. OBI-risankizumab Q8 was the most accepted maintenance regimen (ANS = 9.2 ± 2.0), compared to long interval subcutaneous injections (Q12, Q8 or Q4), more frequent injections (weekly or eow), or intravenous infusions every 4-8 weeks (p < 0.05 for all comparisons). While 57.4% of patients did not experience any adverse event within 24 weeks, the two most frequent adverse events were mild application-site pain (19.0%) and localized erythema (20.7%) with no need for risankizumab discontinuation. Conclusion: OBI-risankizumab therapy is highly accepted and could be the most preferred maintenance regimen in patients with CD.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 19,
  "authors": [
    {
      "name": "Anthony Buisson"
    },
    {
      "name": "Karim Gebara"
    },
    {
      "name": "Bénédicte Caron"
    },
    {
      "name": "Gilles Boschetti"
    },
    {
      "name": "Cyrielle Gilletta de Saint Joseph"
    },
    {
      "name": "Maria Nachury"
    },
    {
      "name": "Hedia Brixi"
    },
    {
      "name": "Pascal Juillerat"
    },
    {
      "name": "Mélanie Serrero"
    },
    {
      "name": "Lucine Vuitton"
    },
    {
      "name": "Xavier Hebuterne"
    },
    {
      "name": "Ludovic Caillo"
    },
    {
      "name": "Antoine Blain"
    },
    {
      "name": "David Laharie"
    },
    {
      "name": "Laurent Peyrin-Biroulet"
    },
    {
      "name": "Romain Altwegg"
    },
    {
      "name": "Guillaume Le Cosquer"
    },
    {
      "name": "Bruno Pereira"
    },
    {
      "name": "Mathurin Fumery"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/av4q870hv3ez2.bib",
  "cited_by": 0,
  "doi": "10.1177/17562848261489118",
  "fulltext_url": null,
  "id": "av4q870hv3ez2",
  "issns": [
    "1756-283X",
    "1756-2848"
  ],
  "landing_url": "https://u-picardie.hal.science/hal-05749179v1",
  "language": "en",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.mhep"
    ],
    [
      "hal",
      "2.sdv.mhep.heg"
    ],
    [
      "openalex",
      "1311|Inflammatory Bowel Disease"
    ]
  ],
  "openalex": "W7212109148",
  "pdf_url": null,
  "pmcid": null,
  "pmid": "42729518",
  "published": "2026-09-10",
  "publisher": "Sage Publishing",
  "ris": "https://research.draconitic.com/paper/av4q870hv3ez2.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:34Z",
      "native_id": "hal-05749179",
      "source": "hal",
      "url": "https://u-picardie.hal.science/hal-05749179v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:1311|Inflammatory Bowel Disease",
      "subfield": "genetics-genomics"
    }
  ],
  "title": "Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study",
  "title_text": "Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:34Z",
  "url": "https://research.draconitic.com/paper/av4q870hv3ez2",
  "venue": "Therapeutic Advances in Gastroenterology",
  "versions": []
}